Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Drillbits & Bottlerockets -- Ignore unavailable to you. Want to Upgrade?

To: Junkyardawg who wrote (6202)	3/22/2001 5:21:39 PM
From: Original Mad Dog	Respond to of 15481

Enbrel tests halted chronic heart failure treatment SEATTLE, March 22 (Reuters) - Drug maker Immunex Corp. (NASDAQ:IMNX) said on Thursday said it will not proceed with phase 2 and 3 testing of its drug Enbrel for treatment of chronic heart failure, but the drug shows positive results in psoriatic arthritis patients. Seattle-based Immunex said it made the decision to stop testing for Enbrel for treatment of chronic heart failure after guidance from an independent data monitoring board indicated the drug, "would not be able to meet efficacy end-points." "Future development decisions for Enbrel in chronic heart failure will be made after we have complete analysis of all data from these studies," said Leslie Garrison, Immunex senior vice president of clinical development. But Immunex and Wyeth-Ayerst Laboratories, a division of American Home Products Corp. (NYSE:AHP), said psoriatic arthritis patients receiving Enbrel experienced "significant improvement in signs and symptoms of their disease compared to placebo." Based on these results, the company plans to file a supplemental biological license application with the U.S. Food and Drug Administration in mid-2001, the companies said.